Latest Regulatory Milestones News

E79 Gold Mines reports exceptional copper, gold, and bismuth assay results from its Mountain Home Project and gains Northern Territory government approval to commence drilling in 2025.

NeuRizer Ltd has resolved key regulatory delays for its NeuRizer Urea Project, significantly cut operating costs, and is forging international partnerships to expand its In Situ Gasification technology.

Quantum Graphite has lodged its final US$300 million financing application with the US EXIM Bank for Project Utile, alongside securing a new exploration license EL7019 in South Australia. The company is poised to release updated JORC 2012 exploration targets soon, underpinning its growth strategy.

Starpharma reports encouraging FDA feedback on its DEP® SN38 candidate for ovarian cancer and prepares for product launches in Saudi Arabia and UAE, supported by a solid $20.3 million cash position.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

CurveBeam AI has reported a record quarter for HiRise™ device purchase orders, driven by a strategic expansion with Stryker in Australia and New Zealand. The company also advanced its FDA regulatory pathway for its BMD module, setting sights on mid-2025 submission.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Truscott Mining Corporation reports significant progress in its Tennant Creek gold projects, underpinned by robust research and plans for expanded drilling funded through new capital raising.

Richmond Vanadium Technology has submitted its draft Environmental Impact Statement for the Richmond - Julia Creek Vanadium Project and progressed innovative metallurgical test work, positioning itself for a development decision in 2025.

TrivarX has secured positive feedback from the FDA on its pivotal trial design for MEB-001, an AI-driven algorithm targeting major depressive episode screening via sleep study data. The company is advancing site collaborations to launch a large-scale US trial.

OncoSil Medical has achieved a key regulatory milestone with MDR certification from BSI, removing post-market restrictions and streamlining its commercial operations across Europe. This approval also paves the way for renewed efforts to enter the Australian market.